BioSpace News Archive

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks Validation of Type II Variation will allow Takeda to commence launches in Europe later this year The pre-filled syringe presentation is designed to enhance the treatment administration experience for HAE patients receiving TAKHZYRO OSAKA, Japan--( BUSINESS WIRE )-- Takeda P

MDNA11, a long acting IL-2 super-agonist shows potent and durable tumor control with strong memory response in tumor models- -Up to 10-fold expansion of cancer-killing immune cells in non-human primates (NHP) without underlying safety issues or immunogenicity-

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) from its ongoing Phase 1/2 study of GB1275 in patien

-- Registrational data in RET fusion-positive NSCLC show 61% ORR in patients previously treated with platinum-based chemotherapy and 73% ORR in treatment-naïve patients -- -- 12% complete response rate in patients with treatment-naïve RET fusion-positive NSCLC -- -- Median DOR not reached across lines of therapy in RET fusion-positive NSCLC, with 6-month DOR of 86% -- -- NDA accepted by FDA and MAA validated by EMA for pralsetinib in RET fusion-positive NSCLC --

Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up CRs are 20%, nearly tripling with two additional years of follow-up Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced new, longer-term data for PD-1 inhibitor Libtayo ® (cem

As states begin to re-open, 40 percent of Americans still view going to the hospital as a risky behavior – even more than going to the hair salon, a concert or the beach, according to a new national survey released tod

Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® achieved a clinically meaningful tumor response in patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer whose disease had progressed following one or more systemic therapies.

Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ

TUKYSA Combination Reduced Risk of Cancer Progression in the Brain or Death by Two-Thirds, Doubled Response Rate and Reduced Risk of Death by Nearly Half Compared to Standard Therapy Alone - - Published Simultaneously in the Journal of Clinical Oncology and Presented in an Oral Session During the Virtual Scientific Program of the 2020 ASCO Annual Meeting - - First Anti-HER2 Oral Therapy in Combination with Standard Medicines to Improve Overall

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reported updated clinical response and translational data from DeCidE1, its Phase 2 study evaluating the safety and efficacy of DPX-Survivac with intermittent low-dose cyclophosphamide (CPA) in patients with recurrent, advanced platinum-sensitive and -resistant ovarian cancer.